An analysis of supply chain strategies in the regenerative medicine industry—Implications for future development

Teng, Chih Wei; Foley, Lucy; O'Neill, Peter; Hicks, C

doi:10.1016/j.ijpe.2013.06.006

Cited by 20 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic is manufactured in a DCM 'node' supported by the centralised 'hub' facility. The benefit of choosing a universal-donor therapeutic model rather than patient-specific, is that one lot to one patient begins the study with the simpler case before turning in due course to the complexity of autologous supply with significantly increased costs [30,31]. These costs are magnified further with DCM due to QC, transportation and logistics [21].…”

Section: Case Studymentioning

confidence: 99%

Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar

2018

View full text Add to dashboard Cite

show abstract

Section: Case Studymentioning

confidence: 99%

Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar

2018

View full text Add to dashboard Cite

show abstract

“…-The first one by Teng et al (2014) on "An analysis of supply chain strategies in the regenerative medicine industry-Implications for future development"…”

Section: ) Foreign Research On Pharmaceutical Situationmentioning

confidence: 99%

Strategic Fit for Outsourcing of Pharmaceutical Manufacturing: A Scenario Study in Thailand

Apithamsoonthorn

View full text Add to dashboard Cite

Outsourcing is recognized as one of the critical factors for efficient execution of pharmaceutical supply chain management, many pharmaceutical companies engage in international outsourcing of services (IOS) to survive in global highly competitive business. Since the key success factors for both domestic & international alliances are partnership characteristics and strategic fit management, but there is no empirical research on this issue in Thai pharmaceutical partnership offshore outsourcing. Therefore, this survey of Thai and foreign companies, both contract providers (CPs) and contract manufacturers (CMs), seeks to indicate significant relationships among both outsourcing strategic fit type and partnership type, including outsourcing performance outcome. This research is two-fold. First, the partnership types (type I, II, & III), the strategic fit types (low fit, moderate fit, & good fit), and their correlations are analyzed. And second, their outsourcing performance (company revenues and growth rates) are presented. The results showed that most of the Thai pharmaceutical outsourcing manufacturing relationships are classified as the partnership type II, as well as the moderate strategic fit, and strongly support the relationship between these two models. However, it is not necessary that the most integrative type of partnership, Type III, will be always the best, because it depends also on the strategic fit between each pair of partners as well. The company revenue and growth rate could predict the company performance outcomes for each of partnership type and strategic fit type. In Thailand, the government policies and strategic goals are the key success factors in this industry.

show abstract

Overview of the Cell Therapy Field

Whitaker

Foley

Ward

2016

Bioprocessing for Cell Based Therapies

View full text Add to dashboard Cite

An analysis of supply chain strategies in the regenerative medicine industry—Implications for future development

Abstract: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence Newcastle University ePrints -eprint.ncl.ac.uk

Cited by 20 publications

References 47 publications

Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar

Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar

Strategic Fit for Outsourcing of Pharmaceutical Manufacturing: A Scenario Study in Thailand

Overview of the Cell Therapy Field

Contact Info

Product

Resources

About